TABLE 2.
Antimicrobial agenta | Asia-West Pacific (n = 16)
|
Europe (n = 5)
|
Latin America (n = 14)
|
North America (n = 15)
|
||||
---|---|---|---|---|---|---|---|---|
% Susceptible | % Resistant | % Susceptible | % Resistant | % Susceptible | % Resistant | % Susceptible | % Resistant | |
Gatifloxacin | 100.0 | 0.0 | 100.0 | 0.0 | 92.9 | 0.0 | 100.0 | 0.0 |
Garenoxacinb | 100.0 | 0.0 | 100.0 | 0.0 | 92.9 | 0.0 | 100.0 | 0.0 |
Levofloxacin | 100.0 | 0.0 | 100.0 | 0.0 | 100.0 | 0.0 | 93.3 | 6.7 |
Ciprofloxacin | 68.8 | 12.5 | 100.0 | 0.0 | 85.7 | 7.1 | 80.0 | 20.0 |
Trimethoprim-sulfamethoxazole | 81.3 | 18.7 | 80.0 | 20.0d | 85.7 | 14.3 | 93.3 | 6.7 |
Piperacillin-tazobactam | 50.0 | 6.3 | 100.0 | 0.0 | 85.7 | 7.1 | 100.0 | 0.0 |
Piperacillin | 37.5 | 50.1 | 100.0 | 0.0 | 85.7 | 14.3 | 93.3 | 0.0 |
Cefepime | 18.8 | 62.5 | 100.0 | 0.0 | 64.3 | 14.3 | 93.3 | 0.0 |
Ceftazidime | 12.5 | 87.5 | 100.0 | 0.0 | 57.1 | 42.9 | 53.3 | 40.0 |
Imipenem | 0.0 | 100.0 | 20.0 | 80.0 | 14.3 | 85.7 | 20.0 | 73.3 |
Amikacin | 6.3 | 81.2 | 20.0 | 0.0 | 14.3 | 28.6 | 20.0 | 26.7 |
Rifampinc | 93.8 | 0.0 | 75.0 | 0.0 | 85.7 | 0.0 | 80.0 | 0.0 |
NCCLS MIC breakpoints for non-Enterobacteriaceae were categorically applied to Chryseobacterium spp. (17).
A susceptibility breakpoint of ≤2 μg/ml was applied (13).
NCCLS MIC breakpoints for Staphylococcus spp. were applied (17).
A C. gleum isolate had an MIC >1/19 μg/ml and was not available for retesting.